Investigating Quantitative Imaging Biomarkers of Response to Cabozantinib in a VCaP Model of Prostate Bone Metastasis

Timothy James Graham¹, Gary Box², Ruth Riisnaes², Susana Miranda², Gerhardt Attard², Johann S. de Bono², Suzanne A. Eccles², Faith E. Davies², Simon P. Robinson¹

With the development of more targeted therapeutics to treat malignant bone disease has come the associated challenge of developing more clinically relevant pre-clinical models, and identifying new non-invasive techniques capable of assessing the tumour phenotype and treatment response. To this end, a mouse model of castrate-resistant, prostate bone metastasis, propagated by direct intraosseous injection of cells, and its response to cabozantinib, has been investigated by quantitative imaging methods.